In conclusion, our results indicated that the MDM2/MDMX inhibitor reversed DOX resistance of human BC by activating the TAB1/TAK1/p38 MAPK pathway, suggesting that the MDM2/MDMX inhibitor in combination with chemotherapy may provide a novel therapeutic strategy for cancer treatment. The gene discussed is MDM4; the disease is cancer.